Probiodrug AG is a biopharmaceutical company focused on the development and commercialisation of new therapeutic products for the treatment of Alzheimer’s disease (“AD”).
Headquartered in Halle, Germany, Probiodrug was founded in 1997 by Prof Dr. Hans-Ulrich Demuth and Dr. Konrad Glund and successfully developed a novel therapeutic concept for diabetes – the DP4 inhibitors / gliptins. Today Probiodrug’s aim is to become a leading company in the development of Alzheimer’s treatments and to thereby provide a better life for patients.
Probiodrug has identified a new therapeutic concept linked to disease initiation and progression. The development approaches are targeting pyroglutamate-Abeta (pGlu-Abeta) as a therapeutic strategy to fight AD.